Cancer Letters
Volume 295, Issue 1 , Pages 110-123 , 1 September 2010

Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells

  • Yue Wang

      Affiliations

    • Department of Immunology, Medical College of Chinese People’s Armed Police Forces, Tianjin, People’s Republic of China
    • Tianjin Key Laboratory for Biomarkers of Occupational and Environmental Hazard, Tianjin, People’s Republic of China
    • Corresponding Author InformationCorresponding author. Address: Department of Immunology, Medical College of Chinese People’s Armed Police Forces, Hedong District Chenlin Road No. 211, Tianjin 300162, People’s Republic of China. Tel.: +86 22 60578099; fax: +86 22 022 24799262.
    • ,
  • Xiu Long Niu

      Affiliations

    • Department of Immunology, Medical College of Chinese People’s Armed Police Forces, Tianjin, People’s Republic of China
    • ,
  • Ye Qu

      Affiliations

    • Department of Microbiology, Medical College of Chinese People’s Armed Police Forces, Tianjin, People’s Republic of China
    • ,
  • Jian Wu

      Affiliations

    • Department of Immunology, Medical College of Chinese People’s Armed Police Forces, Tianjin, People’s Republic of China
    • ,
  • Ya Qin Zhu

      Affiliations

    • Department of Immunology, Medical College of Chinese People’s Armed Police Forces, Tianjin, People’s Republic of China
    • ,
  • Wei Jia Sun

      Affiliations

    • Department of Immunology, Medical College of Chinese People’s Armed Police Forces, Tianjin, People’s Republic of China
    • ,
  • Ling Zhi Li

      Affiliations

    • Tianjin Key Laboratory for Biomarkers of Occupational and Environmental Hazard, Tianjin, People’s Republic of China
    • Department of Pharmaceutical Chemistry, Medical College of Chinese People’s Armed Police Forces, Tianjin, People’s Republic of China

Received 5 December 2009 ,Revised 19 February 2010 ,Accepted 19 February 2010.

References 

  1. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer. 2003;3:502–516
  2. Richardson A, Kaye SB. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist. Updates. 2005;8:311–321
  3. Sehgal PB, Wang L, Rayanade R, Pan H, Margulies L. Interleukin-6-type cytokines. Ann. NY. Acad. Sci. 1995;762:1–14
  4. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007;110:1911–1928
  5. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84:3063–3070
  6. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89:227–234
  7. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995;55:590–596
  8. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology. 2003;37:961–969
  9. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995;55:4633–4639
  10. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin. Cancer Res. 2001;7:2941–2948
  11. Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK, Kuo ML. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate. 2004;60:120–129
  12. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 2001;61:8851–8858
  13. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer. 1994;73:1882–1888
  14. Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M, et al. Interleukin-6 serum levels in patients with gynecological tumors. Int. J. Cancer. 1994;57:318–323
  15. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol. Oncol. 1997;66:27–30
  16. Scambia G, Testa U, Benedetti P, Foti E, Martucci R, Gadducci A, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Brit. J. Cancer. 1995;71:354–356
  17. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int. J. Gynecol. Cancer. 2000;10:33–41
  18. Obata NH, Tamakoshi K, Shibata K, Kikkawa F, Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res. 1997;17:337–342
  19. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005;65:10794–10800
  20. Rabinovich A, Medina L, Piura B, Segal S, Huleihel M. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res. 2007;27:267–272
  21. Wang Y, Yang J, Gao Y, Dong LJ, Liu S, Yao Z. Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma. Cancer Biol. Ther. 2007;6:864–871
  22. Yang J, Wang Y, Gao Y, Shao J, Zhang XJ, Yao Z. Reciprocal regulation of 17beta-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer. Cytokine. 2009;46:382–391
  23. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin. Cancer Res. 1999;5:3445–3453
  24. Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 1997;8:241–252
  25. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem. 1999;274:31648–31654
  26. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res. 1999;5:1007–1014
  27. Lee S, Yoon S, Kim DH. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells. Gynecol. Oncol. 2007;104:338–344
  28. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000;60:5988–5994
  29. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J. Biol. Chem. 2002;277:33490–33500
  30. Ohta T, Ohmichi M, Hayasaka T, Mabuchi S, Saitoh M, Kawagoe J, et al. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology. 2006;147:1761–1769
  31. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002;62:1087–1092
  32. Eliopoulos AG, Kerr DJ, Herrod J, Hodgkins L, Krajewski S, Reed JC, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene. 1995;11:1217–1228
  33. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol. Oncol. 2005;96:287–295
  34. Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, et al. Human ovarian cancer and cisplatin resistance. possible role of inhibitor of apoptosis proteins. Endocrinology. 2001;142:370–380
  35. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000;60:5659–5666
  36. Syed V, Μlinski G, Mok SC, Ho SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J. Natl. Cancer Inst. 2002;94:617–629
  37. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, et al. Inhibition of extracellular signal regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem. 1999;274:31648–31654
  38. Asschert JG, Vellenga E, Ruiters MH, de Vries EG. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int. J. Cancer. 1999;82:244–249
  39. Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine. 2002;17:234–242
  40. Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 2000;20:1061–1067
  41. Goff BA, Paley PJ, Greer BE, Gown AM. Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol. Oncol. 2001;81:18–24
  42. Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, Resnick MB. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol. Oncol. 2006;100:152–159
  43. Schisselbauer JC, Hogan WM, Buetow KH, Tew KD. Heterogeneity of glutathione S-transferase enzyme and gene expression in ovarian carcinoma. Pharmacogenetics. 1992;2:63–72
  44. Lewis AD, Hayes JD, Wole CR. Glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance. intrinsic differences and cell cycle effects. Carcinogenesis. 1998;9:1283–1287
  45. Awasthi S, Sharma R, Singhal SS, Herzog NK, Chaubey M, Awasthi YC. Modulation of cisplatin cytotoxicity by sulphasalazine. Brit. J. Cancer. 1994;70:190–194
  46. Zhang T, Guan M, Jin HY, Lu Y. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. Gynecol. Oncol. 2005;97:501–507
  47. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995;55:4438–4445
  48. Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin-6-mediated upregulation of bcl-xL. Cancer Res. 1995;55:2262–2265
  49. Lin MT, Juan CY, Chang KJ, Chen WJ, Kuo ML. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis. 2001;22:1947–1953
  50. Yamagiwa Y, Marienfeld C, Meng F, Holcik M, Patel T. Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Res. 2004;64:1293–1298
  51. Arimoto-Ishida E, Ohmichi M, Mabuchi S, Takahashi T, Ohshima C, Hay-akawa J, et al. Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin. Endocrinology. 2004;145:2014–2022
  52. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of NFkB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J. Biol. Chem. 2004;279:23477–23485
  53. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin. Cancer Res. 2006;12:5055–5063
  54. Darnell JE. STATs and gene regulation. Science. 1997;277:1630–1635
  55. Levy DE, Darnell JE. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002;3:651–662
  56. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer. 2004;4:97–105
  57. George JA, Chen T, Taylor CC. SRC tyrosine kinase and multidrug resistance protein-1inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res. 2005;65:10381–10388
  58. Savarese TM, Campbell CL, McQuain C, Mitchell K, Guardiani R, Quesenberry PJ, et al. Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas. Cytokine. 2002;17:324–334
  59. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces surviving gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer. Res. 2006;12:11–19

PII: S0304-3835(10)00120-5

doi: 10.1016/j.canlet.2010.02.019

Cancer Letters
Volume 295, Issue 1 , Pages 110-123 , 1 September 2010

Article Tools

* Image Usage & Resolution